Research programme: growth hormone-related compounds - Neuren

Drug Profile

Research programme: growth hormone-related compounds - Neuren

Alternative Names: NNZ-3006

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuren Pharmaceuticals
  • Class Growth hormones
  • Mechanism of Action Insulin-like growth factor I inhibitors; Somatotropin receptor agonists; Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Metabolic disorders; Obesity; Somatotropin deficiency

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in New Zealand
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-disorders in New Zealand
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top